Advances in the treatment for haematological malignancies

Bibliography

• BROWN E, LEWIS PH, NOCERA J: In search of the silver bullet. Fortune (2001) 143:166-170.
   PubMedGoogle Scholar
• LEMONICK MD, PARK A: New hope for cancer. Time (2001) 157:62-69.
   PubMedGoogle Scholar
• GREEN M: Targeting targeted therapy. N. Engl. J. Med. (2004) 350:2191-2193.
   PubMed Web of Science ®Google Scholar
• MANDELLI F, DIVERIO D, AVVISATI G: Molecular remission in PML/RAR α-positive acute promyelocytic leukaemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy: Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood (1997) 90:1014-1021.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, SAWYERS CL, KANTARJIAN H: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344:1038-1042.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348:2609-2617.
   PubMed Web of Science ®Google Scholar
• BOTTLES K: A revolution in genetics: changing medicine, changing lives. Physician Exec. (2001) 27:58-63.
   PubMedGoogle Scholar
• AMOS J, PATNAIK M: Commercial molecular diagnostics in the US: the Human Genome Project to the clinical laboratory. Hum. Mutat. (2002) 19:324-333.
   PubMedGoogle Scholar
• EVANS WE, MCLEOD HL: Pharmacogenomics: drug disposition, drug targets, and side effects. N. Engl. J. Med. (2003) 348:538-549.
   PubMed Web of Science ®Google Scholar
• WEINSHILBOUM R: Inheritance and drug response. N. Engl. J. Med. (2003) 348:529-537.
   PubMed Web of Science ®Google Scholar
• ROSS JS, SCHENKEIN DP, PIETRUSKO R, ROLFE M: Targeted therapies for cancer 2004. Am. J. Clin. Pathol. (2004) 122:598-609
   PubMed Web of Science ®Google Scholar
• CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001) 1:118-129.
   PubMed Web of Science ®Google Scholar
• GOLDENBERG DM: Targeted therapy of cancer with radiolabelled antibodies. J. Nucl. Med. (2002) 43:693-713.
   PubMed Web of Science ®Google Scholar
• REICHERT JM: Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr. Opin. Mol. Ther. (2002) 4:110-118.
   PubMed Web of Science ®Google Scholar
• ROSS JS, GREY K, GREY GS et al.: Anticancer antibodies. Am. J. Clin. Pathol. (2003) 119:472-485.
   PubMed Web of Science ®Google Scholar
• LINENBERGER ML, MALONEY DG, BERNSTEIN ID: Antibody directed therapies for hematological malignancies. Trends Mol. Med. (2002) 8:69-76.
   PubMedGoogle Scholar
• COIFFIER B: Rituximab in the treatment of diffuse large B cell lymphomas. Semin. Oncol. (2002) 29:30-35.
   PubMed Web of Science ®Google Scholar
• COIFFIER B, LEPAGE E, BRIERE J: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B cell lymphoma. N. Engl. J. Med. (2002) 346:235-242.
   PubMed Web of Science ®Google Scholar
• MARCUS R, IMRIE K, BELCH A: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2005) 105:1417-1423.
   PubMed Web of Science ®Google Scholar
• LENZ G, DREYLING M, HOSTER E, WORMANN B: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. (2005) 23:1984-1992.
   PubMed Web of Science ®Google Scholar
• HIDDEMANN W, KNEBA M, DREYLING M: Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone: results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood (2005) 106(12):3725-3732.
   PubMed Web of Science ®Google Scholar
• THIEBLEMONT C, ANTAL D, LACOTTE-THIERRY L: Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer (2005) 104:1434-1441.
   PubMed Web of Science ®Google Scholar
• GORDON LI, WITZIG TE, WISEMAN GA et al.: Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin’s lymphoma. Semin. Oncol. (2002) 29:87-92.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO: Radiolabelled antiCD20 monoclonal antibodies for the treatment of B cell lymphoma. J. Clin. Oncol. (2002) 20:3545-3557.
   PubMed Web of Science ®Google Scholar
• WISEMAN GA, GORDON LI, MULTANI PS et al.: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a Phase II multicenter trial. Blood (2002) 99:4336-4342.
   PubMed Web of Science ®Google Scholar
• HAGENBEEK A, LEWINGTON V: Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann. Oncol. (2005) 16:786-792.
   PubMed Web of Science ®Google Scholar
• NADEMANEE A, FORMAN S, MOLINA A: A Phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood (2005) 106:2896-2902.
   PubMed Web of Science ®Google Scholar
• CHESON BD: Bexxar (Corixa/GlaxoSmithKline). Curr. Opin. Investig. Drugs. (2002) 3:165-170.
   PubMedGoogle Scholar
• HORNING SJ, YOUNES A, JAIN V: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B cell lymphoma, progressive after rituximab. J. Clin. Oncol. (2005) 23:712-719.
   PubMed Web of Science ®Google Scholar
• BENNETT JM, KAMINSKI MS, LEONARD JP: Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukaemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood (2005) 105:4576-4582.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, TUCK M, ESTES J: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. (2005) 352:441-449.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, COLEMAN M, KOSTAKOGLU L: Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I131 tositumomab for untreated follicular lymphoma. J. Clin. Oncol. (2005) 23:5696-5704.
   PubMed Web of Science ®Google Scholar
• VOSE JM, BIERMAN PJ, ENKE C: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J. Clin. Oncol. (2005) 23:461-467.
   PubMed Web of Science ®Google Scholar
• BROSS PF, BEITZ J, CHEN G et al.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukaemia. Clin. Cancer Res. (2001) 7:1490-1496.
   PubMed Web of Science ®Google Scholar
• LARSON RA, BOOGAERTS M, ESTEY E et al.: Antibody-targeted chemotherapy of older patients with acute myeloid leukaemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukaemia (2002) 16:1627-1636.
   PubMed Web of Science ®Google Scholar
• LARSON RA, SIEVERS EL, STADTMAUER EA: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukaemia in first recurrence. Cancer (2005) 1(104):1442-1452.
   Google Scholar
• PICCALUGA PP, MARTINELLI G, RONDONI M: First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk. Res. (2004) 28:987-990.
   PubMed Web of Science ®Google Scholar
• CHEVALLIER P, ROLAND V, MAHE B: Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukaemia. Leuk. Res. (2005) 29:1003-1007.
   PubMed Web of Science ®Google Scholar
• AMADORI S, SUCIU S, STASI R: Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukaemia: final results of AML-15B, a Phase II study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’Adulto Leukaemia Groups. Leukaemia (2005) 19:1768-1773.
   PubMed Web of Science ®Google Scholar
• NABHAN C, RUNDHAUGEN LM, RILEY MB: Phase II pilot trial of gemtuzumab ozogamicin (GO) as first-line therapy in acute myeloid leukaemia patients age 65 or older. Leuk. Res. (2005) 29:53-57.
   PubMed Web of Science ®Google Scholar
• LO-COCO F, CIMINO G, BRECCIA M: Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukaemia. Blood (2004) 104:1995-1999.
   PubMed Web of Science ®Google Scholar
• TAKESHITA A, SHINJO K, NAITO K: Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukaemia (APL) cells. Leukaemia (2005) 19:1306-1311.
   PubMed Web of Science ®Google Scholar
• ARCECI RJ, SANDE J, LANGE B: Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukaemia. Blood (2005) 106:1183-1188.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, FLINN I, JAIN V: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99:3554-3361.
   PubMed Web of Science ®Google Scholar
• RAI KR, FRETER CE, MERCIER RJ: Alemtuzumab in previously treated chronic lymphocytic leukaemia patients who also had received fludarabine. J. Clin. Oncol. (2002) 20:3891-3897.
   PubMed Web of Science ®Google Scholar
• KENNEDY B, RAWSTRON A, CARTER C: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukaemia. Blood (2002) 99:2245-2247.
   PubMed Web of Science ®Google Scholar
• ELTER T, BORCHMANN P, SCHULZ H: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B cell chronic lymphocytic leukaemia: results of a Phase II trial. J. Clin. Oncol. (2005) 23:7024-7031.
   PubMed Web of Science ®Google Scholar
• PAWSON R, DYER MJ, BARGE R: Treatment of T cell prolymphocytic leukaemia with human CD52 antibody. J. Clin. Oncol. (1997) 15:2667-2672.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, CAZIN B, COUTRE S: Campath-1H treatment of T cell prolymphocytic leukaemia in patients for whom at least one prior chemotherapy regimen has failed. J. Clin. Oncol. (2002) 20:205-213.
   PubMed Web of Science ®Google Scholar
• LUNDIN J, HAGBERG H, REPP R: Phase II study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood (2003) 101:4267-4272.
   PubMed Web of Science ®Google Scholar
• KOTTARIDIS PD, MILLIGAN DW, CHOPRA R: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 96:2419-2425.
   PubMed Web of Science ®Google Scholar
• MORRIS E, THOMSON K, CRADDOCK C: Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood (2004) 104:3865-3871.
   PubMed Web of Science ®Google Scholar
• VAN BESIEN K, ARTZ A, SMITH S: Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukaemia and myelodysplastic syndrome. J. Clin. Oncol. (2005) 23:5728-5738.
   PubMedGoogle Scholar
• DELGADO J, THOMSON K, RUSSELL N: Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukaemia: a British society of blood and marrow transplantation study. Blood (2005) 107(4):1724-1730.
   PubMedGoogle Scholar
• LUNDIN J, KIMBY E, BJORKHOLM M: Phase II trial of subcutaneous antiCD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B cell chronic lymphocytic leukaemia (B-CLL). Blood (2002) 100:768-773.
   PubMed Web of Science ®Google Scholar
• GINALDI L, DE MARTINIS M, MATUTES E: Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res. (1998) 22:185-191.
   PubMed Web of Science ®Google Scholar
• HALE G, REBELLO P, BRETTMAN LR: Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukaemia following intravenous or subcutaneous routes of administration. Blood (2004) 104:948-955.
   PubMed Web of Science ®Google Scholar
• WENDTNER CM, RITGEN M, SCHWEIGHOFER CD; GERMAN CLL STUDY GROUP (GCLLSG): Consolidation with alemtuzumab in patients with chronic lymphocytic leukaemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter Phase III trial of the German CLL Study Group (GCLLSG). Leukaemia (2004) 18:1093-1101.
   PubMed Web of Science ®Google Scholar
• MORETON P, KENNEDY B, LUCAS G: Eradication of minimal residual disease in B cell chronic lymphocytic leukaemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. (2005) 23:2971-2979.
   PubMed Web of Science ®Google Scholar
• PICCALUGA PP, MARTINELLI G, MALAGOLA M: Antileukemic and antiGVHD effects of campath-1H in acute lymphoblastic leukaemia relapsed after stem-cell transplantation. Leuk. Lymphoma (2004) 45:731-733.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, COLEMAN M, KETAS JC: Epratuzumab, a humanized antiCD22 antibody, in aggressive non-Hodgkin’s lymphoma: Phase I/II clinical trial results. Clin. Cancer Res. (2004) 10:5327-5334.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, COLEMAN M, KETAS J: Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J. Clin. Oncol. (2005) 23:5044-5051.
   PubMed Web of Science ®Google Scholar
• PARMAR S, TALLMAN MS: Acute promyelocytic leukaemia: a review. Expert Opin. Pharmacother. (2003) 4:1379-1392.
   PubMed Web of Science ®Google Scholar
• SANZ MA, MARTIN G, GONZALEZ M; PROGRAMA DE ESTUDIO Y TRAITMIENTO DE LAS HEMOPATIAS MALIGNAS: Risk-adapted treatment of acute promyelocytic leukaemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood (2004) 103:1237-1243.
   PubMed Web of Science ®Google Scholar
• TALLMAN MS, ANDERSEN JW, SCHIFFER CA: All-trans retinoic acid in acute promyelocytic leukaemia. N. Engl. J. Med. (1997) 337:1021.
   PubMedGoogle Scholar
• BURNETT AK, GRIMWADE D, SOLOMON E, WHEATLEY K, GOLDSTONE AH: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukaemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood (1999) 93:4131-4143.
   PubMed Web of Science ®Google Scholar
• SANZ MA, MARTIN G, GONZALEZ M; PROGRAMA DE ESTUDIO Y TRAITMIENTO DE LAS HEMOPATIAS MALIGNAS: Risk-adapted treatment of acute promyelocytic leukaemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood (2004) 103:1237-1243.
   PubMed Web of Science ®Google Scholar
• FENAUX P, CHASTANG C, CHEVRET S: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukaemia. The European APL Group. Blood (1999) 94:1192-1200.
   PubMed Web of Science ®Google Scholar
• VISANI G, BUONAMICI S, MALAGOLA M, ISIDORI S: Pulsed ATRA as single therapy restores long-term remission in PML-RARα-positive acute promyelocytic leukaemia patients: real time quantification of minimal residual disease. A pilot study. Leukaemia (2001) 15:1696-1700.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ: Imatinib alone and in combination for chronic myeloid leukaemia. Semin. Hematol. (2003) 40:50-58.
   PubMed Web of Science ®Google Scholar
• GOLDMAN JM, MELO JV: Chronic myeloid leukaemia: advances in biology and new approaches to treatment. N. Engl. J. Med. (2003) 349:1451-1464.
   PubMed Web of Science ®Google Scholar
• O’BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N. Engl. J. Med. (2003) 348:994-1004.
   PubMed Web of Science ®Google Scholar
• OTTMANN OG, DRUKER BJ, SAWYERS CL: A Phase II study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukaemias. Blood (2002) 100:1965-1971.
   PubMed Web of Science ®Google Scholar
• PICCALUGA PP, MALAGOLA M, AMABILE M: The achievement of molecular complete remission during treatment with imatinib mesilate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukaemia patients. Haematologica (2004) 89:1269-1271.
   PubMedGoogle Scholar
• VERWEIJ J, VAN OOSTEROM A, BLAY JY et al.: Imatinib mesilate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II study. Eur. J. Cancer (2003) 39:2006-2011.
   PubMed Web of Science ®Google Scholar
• MALAGOLA M, MARTINELLI G, RONDONI M: Imatinib mesilate in the treatment of c-kit-positive acute myeloid leukaemia: is this the real target? Blood (2005) 105:904.
   PubMed Web of Science ®Google Scholar
• SHAH NP, TRAN C, LEE FY, CHEN P, NORRIS D, SAWYERS CL: Over-riding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305:399-401.
   PubMed Web of Science ®Google Scholar
• WEISBERG E, MANLEY PW, BREITENSTEIN W: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7:129-141.
   PubMed Web of Science ®Google Scholar
• GILLILAND DG, GRIFFIN JD: The roles of FLT3 in hematopoiesis and leukaemia. Blood (2002) 100:1532-1542.
   PubMed Web of Science ®Google Scholar
• KELLY LM, YU JC, BOULTON CL et al.: CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukaemia (AML). Cancer Cell (2002) 1:421-432.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL: Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukaemia. Cancer Cell (2002) 1:413-415.
   PubMed Web of Science ®Google Scholar
• MARTINELLI G, PICCALUGA PP, LO COCO F: FLT3 inhibition as tailored therapy for acute myeloid leukaemia. Haematologica (2003) 88:4-8.
   PubMed Web of Science ®Google Scholar
• STONE RM, DEANGELO DJ, KLIMEK V: Patients with acute myeloid leukaemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2005) 105:54-60.
   PubMed Web of Science ®Google Scholar
• SMITH BD, LEVIS M, BERAN M: Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukaemia. Blood (2004) 103:3669-3676.
   PubMed Web of Science ®Google Scholar
• FIEDLER W, SERVE H, DOHNER H: A Phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukaemia (AML) or not amenable to conventional therapy for the disease. Blood (2005) 105:986-993.
   PubMed Web of Science ®Google Scholar
• YEE KW, SCHITTENHELM M, O’FARRELL AM: Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood (2004) 104:4202-4209.
   PubMed Web of Science ®Google Scholar
• SINGHAL S, MEHTA J, DESIKAN R: Antitumour activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341:1565-1571.
   PubMed Web of Science ®Google Scholar
• TOSI P, ZAMAGNI E, CELLINI C: Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica (2002) 87:408-414.
   PubMed Web of Science ®Google Scholar
• PICCALUGA PP, VISANI G, PILERI SA: Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukaemia (2002) 16:1609-1614.
   PubMed Web of Science ®Google Scholar
• CANEPA L, BALLERINI F, VARALDO R: Thalidomide in agnogenic and secondary myelofibrosis. Br. J. Haematol. (2001) 115:313-315.
   PubMed Web of Science ®Google Scholar
• CAVO M, ZAMAGNI E, TOSI P: Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood (2005) 106:35-39.
   PubMed Web of Science ®Google Scholar
• LIST A, KURTIN S, ROE DJ: Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. (2005) 10(352):549-557.
   Google Scholar
• RAJKUMAR SV, HAYMAN SR, LACY MQ: Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood (2005) 106(13):4050-4053.
   PubMed Web of Science ®Google Scholar
• YANG JC, HAWORTH L, SHERRY RM: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349:427-434.
   PubMed Web of Science ®Google Scholar
• TAMM I, DORKEN B, HARTMANN G: Antisense therapy in oncology: new hope for an old idea? Lancet (2001) 358:489- 497.
   PubMed Web of Science ®Google Scholar
• KLASA RJ: Targeting the proapoptotic factor Bcl-2 in non-Hodgkin’s lymphoma. Oncology (Huntingt.) (2004) 18:25-31.
   PubMedGoogle Scholar
• MARCUCCI G, BYRD JC, DAI G: Phase I and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukaemia. Blood (2003) 10:425-432.
   Google Scholar
• BADROS AZ, GOLOUBEVA O, RAPOPORT AP: Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J. Clin. Oncol. (2005) 20(23):4089-4099.
   Google Scholar
• MARCUCCI G, STOCK W, DAI G: Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukaemia: pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. (2005) 20(23):3404-3411.
   Google Scholar
• O’BRIEN SM, CUNNINGHAM CC, GOLENKOV AK, TURKINA AG, NOVICK SC, RAI KR: Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukaemia. J. Clin. Oncol. (2005) 20(23):7697-7702.
   Google Scholar
• ELLIOTT PJ, ROSS JS: The proteasome: a new target for novel drug therapies. Am. J. Clin. Pathol. (2001) 116:637-646.
   PubMed Web of Science ®Google Scholar
• VOORHEES PM, DEES EC, O’NEIL B et al.: The proteasome as a target for cancer therapy. Clin. Cancer Res. (2003) 9:6316-6325.
   PubMed Web of Science ®Google Scholar
• KROPFF MH, BISPING G, WENNING D: Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk. Res. (2005) 29:587-590.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, SONNEVELD P, SCHUSTER MW: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. N. Engl. J. Med. (2005) 16(352):2487-2498.
   Google Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J: Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood (2005) 1(106):2977-2981.
   Google Scholar
• GOY A, YOUNES A, MCLAUGHLIN P: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B cell non-Hodgkin’s lymphoma. J. Clin. Oncol. (2005) 23:667-675.
   PubMed Web of Science ®Google Scholar
• O’CONNOR OA, WRIGHT J, MOSKOWITZ C: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J. Clin. Oncol. (2005) 23:676-684.
   PubMed Web of Science ®Google Scholar
• KARP JE, LANCET JE, KAUFMANN SH: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukaemias: a Phase I clinical-laboratory correlative trial. Blood (2001) 97:3361-3369.
   PubMed Web of Science ®Google Scholar
• KURZROCK R, ALBITAR M, CORTES JE: Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. (2004) 1(22):1287-1292.
   Google Scholar
• CROSSMANN LC, O’BRIEN SM: Imatinib therapy in chronic myeloid leukaemia. Hematol. Oncol. Clin. North Am. (2004) 18:605-617.
   PubMedGoogle Scholar
• KANTARJIAN H, TALPAZ M, O’BRIEN S: High-dose imatinib mesilate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia. Blood (2004) 103:2873-2878.
   PubMed Web of Science ®Google Scholar
• PICCALUGA PP, MALAGOLA M, RONDONI M: Dose increase of imatinib mesilate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. Eur. J. Haematol. (2004) 72:302-303.
   PubMedGoogle Scholar
• GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293:876-880.
   PubMed Web of Science ®Google Scholar
• HOCHHAUS A, KREIL S, CORBIN AS et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukaemia (2002) 16:2190-2196.
   PubMed Web of Science ®Google Scholar
• SCHINDLER T, BORNMANN WG, PELLICENA P, MILLER WT, CLARKSON B, KURIYAN J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289:1938-1942.
   PubMed Web of Science ®Google Scholar
• CORBIN AS, BUCHDUNGER E, PASCAL F, DRUKER BJ: Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem. (2002) 277:32214-32219.
   PubMed Web of Science ®Google Scholar
• BRANFORD S, RUDZKI Z, WALSH S et al.: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood (2003) 102:276-283.
   PubMed Web of Science ®Google Scholar
• SOVERINI S, MARTINELLI G, ROSTI G: ABL mutations in late chronic phase chronic myeloid leukaemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukaemia. J. Clin. Oncol. (2005) 23:4100-4109.
   PubMed Web of Science ®Google Scholar
• CORBIN AS, LA ROSEE P, STOFFREGEN EP, DRUKER BJ, DEININGER MW: Several Bcr-Abl kinase domain mutants associated with imatinib mesilate resistance remain sensitive to imatinib. Blood (2003) 101:4611-4614.
   PubMed Web of Science ®Google Scholar
• GAMBACORTI-PASSERINI C, GUNBY RH, PIAZZA R, GALIETTA A, ROSTAGNO R, SCAPOZZA L: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. (2003) 4:75-85.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN JN: Pharmacogenomics: teaching old drugs new tricks. N. Engl. J. Med. (2000) 343:1408-1409.
   PubMed Web of Science ®Google Scholar
• SLONIM DK: Transcriptional profiling in cancer: the path to clinical pharmacogenomics. Pharmacogenomic (2001) 2:123-136.
   PubMedGoogle Scholar